Simon Sylvain, Labarriere Nathalie
CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
LabEx IGO "Immunotherapy, Graft, Oncology," Nantes, France.
Oncoimmunology. 2017 Sep 14;7(1):e1364828. doi: 10.1080/2162402X.2017.1364828. eCollection 2017.
Inhibitory properties of PD-1 receptor engagement on activated T cells are well established in physiologic and pathological contexts. In cancer, the use of checkpoint blockade, such as anti-PD-1 antibodies, becomes progressively a reference treatment of a growing number of tumors. Nonetheless, it is also established that PD-1 expression on antigen-specific T cells reflects the functional avidity and anti-tumor reactivity of these T cells. We will discuss this dual significance of PD-1 expression on tumor-specific T cells, due to a complex regulation and the opportunity to exploit this expression to define, monitor and exploit tumor-reactive T cells for immunotherapy purposes.
在生理和病理环境中，PD-1受体与活化T细胞结合的抑制特性已得到充分证实。在癌症领域，诸如抗PD-1抗体之类的检查点阻断疗法逐渐成为越来越多肿瘤的参考治疗方法。然而，也有研究表明，抗原特异性T细胞上的PD-1表达反映了这些T细胞的功能亲和力和抗肿瘤反应性。由于存在复杂的调控机制，以及利用这种表达来定义、监测和开发用于免疫治疗目的的肿瘤反应性T细胞的机会，我们将讨论PD-1在肿瘤特异性T细胞上表达的这种双重意义。
